SynthesisBMJ open2014
The assessment and impact of sarcopenia in lung cancer: a systematic literature review.
Synthesis in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Protein intake and muscle mass maintenance in patients with cancer types with high prevalence of sarcopenia: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Nutritional status and clinical outcomes in pediatric patients with solid tumors : A systematic review of the literature.Seminars in oncology · 2019Pooled it
- Pooled it
- Beyond tumor burden: PET/CT-derived psoas muscle quality and survival outcomes in metastatic NSCLC patients treated with nivolumab.BMC cancer · 2026Article
- Skeletal muscle loss and associated clinical outcomes in patients with small-cell lung cancer receiving concurrent chemoradiotherapy.BMC cancer · 2025Article
- HISLIS: Histology, Sarcopenia, and Lung Inflammation Score-A New Perspective for Lung Cancer Patients?Life (Basel, Switzerland) · 2025Article
- Article
- Psoas Muscle Volume Is a Useful Predictor of Postoperative Outcome in Elderly Patients With Non-Small Cell Lung Cancer.Thoracic cancer · 2025Article
- Evaluation of nutritional parameters that may be associated with survival in patients with locally advanced non-small cell lung carcinoma receiving definitive concurrent chemoradiotherapy: retrospective study conducted in a tertiary pulmonary hospital.Japanese journal of radiology · 2025Article
- Overview and current status of published research on cancer, sarcopenia and physical activity: A bibliometric analysis.AIMS public health · 2025Review
- Three-dimensional numerical schemes for the segmentation of the psoas muscle in X-ray computed tomography images.BMC medical imaging · 2024Article
- How General and Inflammatory Status Impacts on the Prognosis of Patients Affected by Lung Cancer: State of the Art.Biomedicines · 2024Review
- Diagnosis of sarcopenia on thoracic computed tomography and its association with postoperative survival after anatomic lung cancer resection.Scientific reports · 2023Article
- CT-Derived Sarcopenia and Outcomes after Thoracoscopic Pulmonary Resection for Non-Small Cell Lung Cancer.Cancers · 2023Article
- Sarcopenia as a Prognostic Marker in Elderly Head and Neck Squamous Cell Carcinoma Patients Undergoing (Chemo-)Radiation.Cancers · 2022Article
- Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma.Scientific reports · 2022Article
- Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review.Discover oncology · 2022Review
- Cancer, Phase Angle and Sarcopenia: The Role of Diet in Connection with Lung Cancer Prognosis.Lung · 2022Review
- Serum creatinine and cystatin C-based diagnostic indices for sarcopenia in advanced non-small cell lung cancer.Journal of cachexia, sarcopenia and muscle · 2022Article
- Impact of Sarcopenia and Bone Mineral Density on Implant Failure after Dorsal Instrumentation in Patients with Osteoporotic Vertebral Fractures.Medicina (Kaunas, Lithuania) · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesThere is growing awareness of the relationship between sarcopenia (loss of muscle mass and function), and outcomes in cancer, making it a potential target for future therapies. In order to inform future research and practice, we undertook a systematic review of factors associated with loss of muscle mass, and the relationship between muscle function and muscle mass in lung cancer, a common condition associated with poor outcomes.
designWe conducted a computerised systematic literature search on five databases. Studies were included if they explored muscle mass as an outcome measure in patients with lung cancer, and were published in English.
settingSecondary care.
participantsPatients with lung cancer. PRIMARY OUTCOME: Factors associated with loss of muscle mass and muscle function, or sarcopenia, and the clinical impact thereof in patients with lung cancer.
resultsWe reviewed 5726 citations, and 35 articles were selected for analysis. Sarcopenia, as defined by reduced muscle mass alone, was found to be very prevalent in patients with lung cancer, regardless of body mass index, and where present was associated with poorer functional status and overall survival. There were diverse studies exploring molecular and metabolic factors in the development of loss of muscle mass; however, the precise mechanisms that contribute to sarcopenia and cachexia remain uncertain. The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results. There are very limited data on the correlation between degree of sarcopenia and muscle function, which has a non-linear relationship in older non-cancer populations.
conclusionsLoss of muscle mass is a significant contributor to morbidity in patients with lung cancer. Loss of muscle mass and function may predate clinically overt cachexia, underlining the importance of evaluating sarcopenia, rather than weight loss alone. Understanding this relationship and its associated factors will provide opportunities for focused intervention to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.